Year: 2019

Please note that this information is announced in the Other Information category.INVL Asset Management, one of Lithuania’s leading asset management companies, is reorganizing the portfolio of investment funds it manages. In the first half of November this year, the INVL Absolute Return Subfund was closed by decision of the company. In addition, the INVL Emerging Europe ex Russia TOP20 Subfund will be merged into the INVL Baltic Fund. The Bank of Lithuania approved the merger on 18 November; its completion is planned on 15 January 2020.“Having until now increased the number of mutual funds, at this stage we’ve reviewed the palette of funds considering efficiency for clients. We decided to halt the INVL Absolute Return Subfund, which did not reach critical asset size, and we are merging the INVL Emerging Europe ex Russia TOP20 Subfund into...

The Japan Patent Office has granted a patent regarding Iconovo’s dry powder inhaler, ICOres. Iconovo has already several granted ICOres patents in Sweden and in Europe, but this is the first in Japan. ICOres is the dry powder inhaler used in Iconovo’s two major customer projects including generic SymbicortÒ. ”A granted patent is the key to this huge and important market. This will be an advantage to our customers when launching ICOres products in Japan”, says Dr Orest Lastow, CEO.For further information please contact:Orest Lastow, VD, orest.lastow@iconovo.se, telephone: 076-5422220.About ICOresICOres is a novel reservoir-based dry powder inhaler developed by Iconovo. It can be designed in many different shapes and colors and customized to meet a customer’s unique requirements. ICOres has two separate reservoirs and is particularly suitable...

Den japanska patentmyndigheten har godkänt ett patent avseende Iconovos inhalator, ICOres. Iconovo har sedan tidigare flera godkända svenska patent samt ett europeiskt patent på ICOres, men detta är det första i Japan. ICOres är den inhalator som används i Iconovos två stora kundprojekt där bland annat generisk SymbicortÒ ingår.”Ett godkänt patent är nyckeln till den stora och viktiga japanska marknaden. Det är en fördel för våra befintliga kunder som ska kunna lansera ICOres-produkter i Japan”, säger Orest Lastow, VD.För ytterligare information, vänligen kontakta Orest Lastow, VD, orest.lastow@iconovo.se, mobil: 076-5422220.Om ICOresICOres är en nyskapande reservoarbaserad torrpulverinhalator som är utvecklad av Iconovo. Den kan anpassas för att ha flera olika yttre former och färger för att passa olika kunders speciella krav. ICOres...

為 SABCS 新聞節目的選擇摘要在 12 月 13 日口述匯報了口服紫杉醇和 encequidar 的第三期研究結果公司為投資界舉辦了關鍵意見領袖的網上直播活動美國紐約州水牛城, Nov. 19, 2019 (GLOBE NEWSWIRE) — Athenex, Inc. (NASDAQ: ATNX) 是一家國際生物製藥公司，致力研究、開發及將用於治療癌症和相關疾病的新療法商業化。該公司宣布今天已為 2019 San Antonio Breast Cancer Symposium (SABCS) 的發佈活動選擇發表治療轉移性乳癌的口服紫杉醇和 encequidar（口服紫杉醇）的第三期研究結果摘要。 公司將於 2019 年 12 月 13 日（星期五）在德州的 San Antonio 市舉行的 SABCS 上作口頭匯報。在口述匯報後，公司計劃為投資界舉行關鍵意見領袖 (KOL) 網上直播活動來討論研究結果。Athenex 主席暨行政總裁 Johnson Lau 醫生表示：「我們期待在 SABCS 上提供更多關於治療轉移性乳癌的關鍵性口服紫杉醇第三期研究數據和分析。我們很高興有機會與腫瘤學家、患者和研究人員分享這些最新資訊，以強調口服紫杉醇對轉移性乳癌患者可產生正面影響的潛力。」只會在 SABCS 網站上發佈為新聞活動選擇的摘要標題，直至 12 月 13 日禁止發佈解除為止，屆時，將會在網上發佈完整的摘要。KOL 網上直播活動在口述匯報後，公司計劃於 2019 年 12 月 13 日在投資界的網上直播活動中審視在 SABCS 上提交的第三期臨床數據。將於獨立發表的公告中提供更多詳情。Athenex 展覽攤位誠邀 SABCS 的參加者於 12 月 10 日 至 13 日每天上午 10 時 45 分至下午 5 時參觀 Athenex Oncology 在會議上的展覽攤位（攤位＃ 627/629）。  Orascovery 平台最初由 Hanmi Pharmaceuticals...

Abstract selected for the SABCS press programOral presentation of Oral Paclitaxel and encequidar Phase III results on December 13Company to host a Key Opinion Leader webcast event for the investment communityBUFFALO, N.Y., Nov. 19, 2019 (GLOBE NEWSWIRE) — Athenex, Inc. (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, announced today that its abstract for the Phase III study of oral paclitaxel and encequidar (Oral Paclitaxel) in metastatic breast cancer has been selected for the press program of the 2019 San Antonio Breast Cancer Symposium (SABCS). The Company will deliver an oral presentation at SABCS, taking place in San Antonio, Texas, on Friday, December 13, 2019. After the oral presentation,...

VANCOUVER, British Columbia, Nov. 19, 2019 (GLOBE NEWSWIRE) — ElectraMeccanica Vehicles Corp. (NASDAQ: SOLO) (“ElectraMeccanica” or the “Company”), a designer and manufacturer of electric vehicles, is opening its first retail kiosk to showcase its all-electric, single-seat SOLO. Potential customers will have the opportunity to view, drive and place pre-orders for the much-anticipated SOLO, to be released in 2020.The kiosk is located in the highly trafficked Westfield Century City Shopping Mall in Los Angeles, California. It will be open during the 2019 Holiday Season from 10:00 a.m. to 9:00 p.m. daily, starting Black Friday, November 29, 2019 through Sunday, January 5, 2020. Westfield Century City Shopping Mall is conveniently located amongst the surrounding Beverly Hills, Bel Air, Santa Monica and Century City communities. ElectraMeccanica...

Estimated 1,000 Commercial Campaign to Follow Success of Prior SiriusXM Marketing CampaignsEAST RUTHERFORD, NJ, Nov. 19, 2019 (GLOBE NEWSWIRE) — MamaMancini’s Holdings, Inc. (OTCQB: MMMB), a marketer of specialty pre-prepared, frozen and refrigerated all-natural food products, has launched a new SiriusXM national radio campaign, which will air an estimated 1,000 commercials over the Thanksgiving holiday. Sirius XM Holdings Inc. is the world’s largest audio entertainment company, reaching more than 65 million people with its audio products and services.The campaign, which commenced on November 18, 2019, follows the success of four prior radio campaigns through SiriusXM. MamaMancini’s expects to air up to 1,000 commercials on major SiriusXM radio channels including, but not limited to, CNN, Fox, Fox HLN, CNN HLN, MSNBC,...